Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUE-101 in HPV16+ recurrent/metastatic head and neck cancer
NCT03978689Phase 1Completed
- Sponsor
- Cue Biopharma
- Start
- Jul 2019
- Primary completion
- Jan 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of CUE-101 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Cue Biopharma. Primary endpoints: Dose Limiting Toxicity at 36 months and Pharmacokinetics at 36 months. Started Jul 2019; status: completed.
02
Drugs
CUE-101
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03978689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978689.